Prognostic Value of Tissue Factor (TF) in Blood t in Colorectal Cancer in Adults

Last updated: June 25, 2019
Sponsor: University Hospital, Lille
Overall Status: Active - Recruiting

Phase

1

Condition

Colorectal Cancer

Colon Cancer

Cancer

Treatment

N/A

Clinical Study ID

NCT02304978
2008-09/0908
2009-A00264-53
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Severity of colorectal cancer (CRC) is evaluated by its local staging, locoregional and general ( presence of metastases , usually liver ). This is the most common cancer in France and, despite surgical treatment of the primary tumor, it is still subject to a high mortality rate due to metastatic evolution, mainly hepatic .

There is currently no specific marker for predicting cancer, the same hardly changed , which would modulate the aggressive therapeutic strategy . antigen (CEA) is used in the monitoring of JRC made.Tissue factor (TF) is the VII tissue factor receptor. it initiates the coagulation cascade. it was noted as a true cell marker tumorale1 aggressiveness. Corroborating evidence that the way the TF plays an important role in the invasive and metastatic potential of CRC. First, various human cancer cell lines express the FT colic. Furthermore, there is a relationship between the importance of monocyte TF expression and the evolutionary potential of human CRC.

The investigators hypothesize that these interest intra-platelet and plasma markers are a reflection of tumor angiogenic potential. And the investigators will verify the superiority of their preoperative levels in the CRC group compared with the control group, normalization of postoperative after surgical resection rates and their possible re-ascent in case of tumor recurrence in the CRC group.

The levy to one month in controls allow us to verify the absence of secondary modification to laparotomy, the colectomy and general anesthesia.

The investigators assume that the rate of soluble TF in peripheral blood of the holders of CRC patients may be a marker of invasion and aggression (i.e. prognosis).

Eligibility Criteria

Inclusion

Inclusion Criteria: All patients, adults, holders of CRC with or without MH in whom surgical resection HEALINGis planned . For witnesses:

  • Patients without CCR (preoperative colonoscopy). This control population will verifynormal values regulators of angiogenesis recently defined and specificity of thesevis-à-vis markers CCR-

Exclusion

Exclusion Criteria: all situations where the plasma levels of FT antigen are high, in particular:

  • Patients with unstable angina or myocardial infarction in the acute phase (not olderthan two months)

  • Severe sepsis (hospitalization)

  • Cirrhosis stage Child C

  • Chronic renal failure requiring renal replacement extra

  • Patients with microvascular complications of diabetes

  • Vasculitis

  • Pregnancy and lactation patient on oral contraceptives, or having hormone replacementtherapy for menopause

  • Patients with extrahepatic metastases

  • Patients underwent emergency surgery

  • Persons not able to consent For witnesses: History of cancer, inflammatory disease, diabetes, regular intake of anti inflammatorydrugs. If during colonoscopy, colorectal cancer was detected, the control patients were excludedfrom the study -

Study Design

Total Participants: 120
Study Start date:
June 22, 2009
Estimated Completion Date:
June 30, 2020

Study Description

The study is to measure the TF in the blood, as well as ACE, C reactive protein and E-selectin. The TF will also be measured in the tissue removed during surgery.

Connect with a study center

  • Service de Chirurgie Digestive et de transplantation Hôpital Claude HURIEZ

    Lille, 59037
    France

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.